Updates | Pfizer

In Their Own Voices: A Song By and For Those Touched by Rare Disease

Read more about In Their Own Voices: A Song By and For Those Touched by Rare Disease

Although individually they are classified as “rare,” considered together, rare diseases affect as many as 1 in 10 people in the United States. Globally, rare diseases impact 3.5%-5.9% of the world’s population.

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Read more about Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

New York & Saint-Herblain (France), February 17, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer, as the study sponsor, has decided to discontinue a significant percentage of participants in the U.S. who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study.

Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program

Read more about Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program

Phase 1/2 trial will enroll up to 900 healthy U.S.

Closing the Cancer Care Gap: World Cancer Day and Beyond

Read more about Closing the Cancer Care Gap: World Cancer Day and Beyond

February 4, 2023, marks World Cancer Day, an annual awareness day spearheaded by the Union for International Cancer Control (UICC) and dedicated to uniting the world in the fight against cancer.

Pfizer Responds to Research Claims

Read more about Pfizer Responds to Research Claims

New York, N.Y., January 27, 2023 – Allegations have recently been made related to gain of function and directed evolution research at Pfizer and the company would like to set the record straight.

Pfizer and International Trachoma Initiative Deliver One Billionth Zithromax® Dose Toward Trachoma Elimination by 2030

Read more about Pfizer and International Trachoma Initiative Deliver One Billionth Zithromax® Dose Toward Trachoma Elimination by 2030

NEW YORK, January 30, 2023 – Pfizer Inc. (NYSE: PFE) and the International Trachoma Initiative (ITI), a program of the independent nonprofit Task Force for Global Health, today announced the donation of the one billionth Zithromax® (azithromycin) dose as part of the World Health Organization’s (WHO) recommended S.A.F.E. strategy to help prevent and treat trachoma.

Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Read more about Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

New York, NY, January 27, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (cMA) for PAXLOVID^TM (nirmatrelvir tablets and ritonavir tablets) to standard (also referred to as “full”) Marketing Authorization (MA) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.

Juneteenth and the Path Forward

Read more about Juneteenth and the Path Forward

At Pfizer, our Purpose – breakthroughs that change patients’ lives – will not be achieved if we don’t work with our colleagues, our partners, and the communities we serve to increase equity in our healthcare system, reduce bias in our workplace, and build more inclusive communities.

Data Privacy Day and Our Commitment to You

Read more about Data Privacy Day and Our Commitment to You

Every year on January 28, the United States, Canada, Nigeria, Israel, and 47 European countries come together to raise awareness and promote privacy and data protection best practices.

Pfizer to Acquire Sanford, North Carolina Manufacturing Site from Abzena

Read more about Pfizer to Acquire Sanford, North Carolina Manufacturing Site from Abzena

NEW YORK & SAN DIEGO, January 17, 2023 – Pfizer Inc. (NYSE: PFE) and Abzena today announced that the companies have entered into an agreement under which Pfizer will acquire Abzena’s manufacturing facility in Sanford, North Carolina. Upon completion of the construction, the state-of-the-art facility will have extensive capabilities for producing biologics drug substance and provides additional manufacturing capacity allowing Pfizer to help accelerate its innovative pipeline. In addition, Abzena and Pfizer’s CentreOne contract manufacturing organization will seek to collaborate to advance complex biologic products to market.

Subscribe to Updates